Trials / Terminated
TerminatedNCT00599820
Use of Intravitreal Bevacizumab in Eyes With Choroidal Neovascularization Secondary to Angioid Streaks
OCT, Visual Outcome and Angiographic Analysis of Choroidal Neovascularization in Six Eyes With Angioid Streaks Treated With a Single Intravitreal Injection of Bevacizumab
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Asociación para Evitar la Ceguera en México · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Intravitreal Bevacizumab is an effective treatment for choroidal neovascularization secondary to Angioid Streaks
Detailed description
A consecutive case series of patients with angioid streaks that developed subfoveal choroidal neovascularization were treated with a primary 2.5 mg injection of Bevacizumab (Avastin) intravitreally. All patients were evaluated with BCVA at 1, 2 , 4 and 12 weeks and OCT and fluoresceine angiography at month 1 and 3. (Patients will be follow 6 months)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Intravitreal Bevacizumab |
Timeline
- Start date
- 2005-11-01
- Primary completion
- 2005-11-01
- Completion
- 2006-05-01
- First posted
- 2008-01-24
- Last updated
- 2024-06-03
Locations
1 site across 1 country: Mexico
Source: ClinicalTrials.gov record NCT00599820. Inclusion in this directory is not an endorsement.